ENSC
ENSC
NASDAQ · Biotechnology

Ensysce Biosciences Inc

$0.54
+0.02 (+4.77%)
As of Mar 31, 10:16 PM ET ·
Financial Highlights (FY 2026)
Revenue
29.48M
Net Income
-45,191,962
Gross Margin
Profit Margin
-153.3%
Rev Growth
+13.9%
D/E Ratio
0.08
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 48.7% 48.7%
Operating Margin -129.2% -116.3% -7.6% -7.6%
Profit Margin -153.3% -145.6% -6.6% -5.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 29.48M 25.89M 257.5K 229.4K
Gross Profit 125.5K 111.8K
Operating Income -38,081,448 -30,101,267 -19,525 -17,347
Net Income -45,191,962 -35,721,733 -16,876 -13,616
Gross Margin 48.7% 48.7%
Operating Margin -129.2% -116.3% -7.6% -7.6%
Profit Margin -153.3% -145.6% -6.6% -5.9%
Rev Growth +13.9% +13.9% +2.0% +15.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 74.4K 74.4K 414.2K 358.8K
Total Equity 919.1K 919.1K 1.33M 1.24M
D/E Ratio 0.08 0.08 0.31 0.29
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -37,890,710 -31,614,416 -21,131 -19,685
Free Cash Flow -13,268 -16,406